Sorry, not familiar with VSTM but did a little reading about the drug. This is very very early, only a phase 1/1B trial so they have a ways to go yet. For those interested, here is a copy and past of what V-6063 is. I also do not know about FAK inhibitors either, but I will read up. Thanks for bringing this to the board, always interesting to read about emerging technologies.
VS-6063 is an oral small molecule inhibitor of focal adhesion kinase (FAK) which is a critical pathway for cancer stem cells. VS-6063 was well-tolerated and demonstrated signs of clinical activity in a Phase 1 study in advanced solid tumors. VS-6063 is currently in a Phase 1/1b study in patients with advanced ovarian cancer, where VS-6063 is being tested in combination with paclitaxel. VS-6063 is anticipated to enter a potentially pivotal study in mesothelioma midyear 2013.
O.K. Chinesehampsters, From what I read, the managemnt and board
are of very strong pedigree. If is such a small word, but if
v-6063 is effective with taxol in any heavily pretreated population,
the stock could get interresting, If again, their biomarkers are accurate
to screen for csc then again interresting. Worth keeping an eye on.
I have no position in the stock, but wanted to ask you savvy guys
what you thought, thanks for the return.